Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock-inferred dates: Evidence that older age, heterosexual risk group and more recent diagnosis are prognostic factors.
Greece
HIV
infection dates
late presentation
molecular epidemiology
risk factors
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
26
07
2022
accepted:
15
09
2022
pubmed:
20
10
2022
medline:
3
12
2022
entrez:
19
10
2022
Statut:
ppublish
Résumé
HIV late presentation (LP) has been increasing in recent years in Europe. Our aim was to investigate the characteristics of LP in Greece using in addition to the traditional definition for LP, the time interval between HIV infection and diagnosis. Our nationwide sample included HIV-1 sequences generated from 6166 people living with HIV (PLWH) in Greece during the period 1999-2015. Our analysis was based on the molecularly inferred HIV-1 infection dates for PLWH infected within local molecular transmission clusters of subtypes A1 and B. Analysis of the determinants of LP was conducted using either CD4 counts or AIDS-defining condition at diagnosis or the time from infection to diagnosis. Older age, heterosexual transmission risk group and more recent diagnosis were associated with increased risk for LP. In contrast to previous studies, people who inject drugs (PWID) had a shorter median time to diagnosis (0.63 years) compared to men who have sex with men (MSM) (1.72 years) and heterosexuals (2.43 years). Using HIV infection dates that provide an unbiased marker for LP compared to CD4 counts at diagnosis, which are age-dependent, we estimated that the time to diagnosis increased gradually with age. Migrants infected regionally do not differ with respect to LP status compared to native Greeks. We demonstrate that older people and heterosexuals are among those at higher risk for LP; and given the growing number of older people among newly diagnosed cases, tailored interventions are needed in these populations.
Identifiants
pubmed: 36258653
doi: 10.1111/hiv.13415
pmc: PMC10092532
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1152Informations de copyright
© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
AIDS Res Hum Retroviruses. 2021 Nov;37(11):846-851
pubmed: 33461392
J Int AIDS Soc. 2015 Nov 18;18:20317
pubmed: 26584954
Pathogens. 2021 Jul 02;10(7):
pubmed: 34357985
Addiction. 2015 Sep;110(9):1453-67
pubmed: 26032121
BMC Public Health. 2016 Aug 25;16(1):878
pubmed: 27557878
HIV Med. 2022 Dec;23(11):1143-1152
pubmed: 36258653
Euro Surveill. 2021 Nov;26(47):
pubmed: 34823639
Viruses. 2020 Oct 19;12(10):
pubmed: 33086773
HIV Med. 2023 Jan;24(1):75-81
pubmed: 35662378
Sci Rep. 2016 Dec 05;6:38100
pubmed: 27917890
Infect Genet Evol. 2021 Jul;91:104799
pubmed: 33677110
AIDS Care. 2014;26 Suppl 1:S83-93
pubmed: 24731147
Antivir Ther. 2011;16(7):1103-12
pubmed: 22024526
Genitourin Med. 1996 Feb;72(1):27-31
pubmed: 8655163
HIV Med. 2012 Mar;13(3):172-81
pubmed: 22093171
J Int AIDS Soc. 2012 Oct 11;15(2):17395
pubmed: 23305650
HIV Med. 2011 Jan;12(1):61-4
pubmed: 20561080
Int J STD AIDS. 2012 Jul;23(7):475-80
pubmed: 22844000
Lancet HIV. 2022 Apr;9(4):e269-e280
pubmed: 35218732
J Infect Dis. 2011 Oct 1;204(7):1095-103
pubmed: 21881125
Clin Infect Dis. 2013 Mar;56(6):888-97
pubmed: 23223594
Subst Abuse Treat Prev Policy. 2022 Feb 10;17(1):11
pubmed: 35144631
Viruses. 2022 Jan 06;14(1):
pubmed: 35062305
Sci Rep. 2018 Jun 5;8(1):8594
pubmed: 29872068